Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;69(7):1816-1832.
doi: 10.1002/glia.23997. Epub 2021 Mar 22.

Astrocyte-mediated purinergic signaling is upregulated in a mouse model of Fragile X syndrome

Kathryn E Reynolds  1 , Chloe R Wong  2 , Angela L Scott  1   2
Affiliations

Astrocyte-mediated purinergic signaling is upregulated in a mouse model of Fragile X syndrome

Kathryn E Reynolds et al. Glia. 2021 Jul.

Abstract

Fragile X syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorders. With increasing investigation into the molecular mechanisms underlying FXS, there is growing evidence that perturbations in glial signaling are widely associated with neurological pathology. Purinergic signaling, which utilizes nucleoside triphosphates as signaling molecules, provides one of the most ubiquitous signaling systems for glial-neuronal and glial-glial crosstalk. Here, we sought to identify whether purinergic signaling is dysregulated within the FXS mouse cortex, and whether this dysregulation contributes to aberrant intercellular communication. In primary astrocyte cultures derived from the Fmr1 knockout (KO) mouse model of FXS, we found that application of exogenous ATP and UTP evoked elevated intracellular calcium responses compared to wildtype levels. Accordingly, purinergic P2Y2 and P2Y6 receptor expression was increased in Fmr1 KO astrocytes both in vitro and in acutely dissociated tissue, while P2Y antagonism via suramin prevented intracellular calcium elevations, suggesting a role for these receptors in aberrant FXS astrocyte activation. To investigate the impact of elevated purinergic signaling on astrocyte-mediated synaptogenesis, we quantified synaptogenic protein TSP-1, known to be regulated by P2Y activation. TSP-1 secretion and expression were both heightened in Fmr1 KO vs wildtype astrocytes following UTP application, while naïve TSP-1 cortical expression was also transiently elevated in vivo, indicating increased potential for excitatory TSP-1-mediated synaptogenesis in the FXS cortex. Together, our results demonstrate novel and significant purinergic signaling elevations in Fmr1 KO astrocytes, which may serve as a potential therapeutic target to mitigate the signaling aberrations observed in FXS.

Keywords: ATP; Fragile X syndrome; P2Y; UTP; astrocyte; cortex; purinergic signaling; thrombospondin-1.

PubMed Disclaimer

References

REFERENCES

    1. Abbracchio, M. P., Burnstock, G., Verkhratsky, A., & Zimmermann, H. (2009). Purinergic signalling in the nervous system: An overview. Trends in Neurosciences, 32(1), 19-29. https://doi.org/10.1016/j.tins.2008.10.001
    1. Adams, J. B., Audhya, T., McDonough-Means, S., Rubin, R. A., Quig, D., Geis, E., … Lee, W. (2011). Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutrition & Metabolism (London), 8(1), 34. https://doi.org/10.1186/1743-7075-8-34
    1. Alves, M., Gomez-Villafuertes, R., Delanty, N., Farrell, M. A., O'Brien, D. F., Miras-Portugal, M. T., … Engel, T. (2017). Expression and function of the metabotropic purinergic P2Y receptor family in experimental seizure models and patients with drug-refractory epilepsy. Epilepsia, 58(9), 1603-1614. https://doi.org/10.1111/epi.13850
    1. Apolloni, S., Finocchi, P., D'Agnano, I., Alloisio, S., Nobile, M., D'Ambrosi, N., & Volonte, C. (2010). UDP exerts cytostatic and cytotoxic actions in human neuroblastoma SH-SY5Y cells over-expressing P2Y6 receptor. Neurochemistry International, 56(5), 670-678. https://doi.org/10.1016/j.neuint.2010.02.003
    1. Arlt, W., Reincke, M., Siekmann, L., Winkelmann, W., & Allolio, B. (1994). Suramin in adrenocortical cancer: Limited efficacy and serious toxicity. Clinical Endocrinology, 41, 299-307.

Publication types

Substances

Grants and funding

LinkOut - more resources